Archive | Funding Opportunities RSS for this section

BioCanRx Priority Funding Call LOI Due 01-Nov-2017

*PRIORITY FUNDING CALL: BioCanRx is pleased to announce that the next call for applications is now open in all of the Catalyst, Enabling, Clinical Trial, and Clinical, Social & Economic Impact (CSEI) programs. At this time, BioCanRx is placing highest priority on the intake of new applications for funding, proposing research activities that would be likely to add value to, facilitate the implementation of, or enhance the translation to clinic of, technologies within the existing BioCanRx portfolio of research investments. The projects contained within the BioCanRx research portfolio are found here. Of important note, new applications will be expected to speak very specifically to the value-add of their proposed research deliverables and the complementarity to support the successful development of BioCanRx technologies or research projects.

Funding timelines: Applicants should be aware that all projects must plan to be completed no later than March 31, 2020. Given this time constraint, it is unlikely that new clinical trial projects will be funded in this next call for proposals, unless the trial is of a small pilot scale AND the applicant(s) can convincingly demonstrate feasibility of completion of the study by March 31, 2020.

Application deadlines: Next LOI submission deadline will be 11:59 am EST on November 1, 2017 invited full applications are anticipated by mid-February (date TBD) for funding to commence by April 1, 2018.

Find application process and instructions here.

CCO Call for Research Proposals – Analytics and Informatics  ** DEADLINE: Friday, August 18th by 5 pm (EDT)

 

Analytics and Informatics (A&I) at CCO is calling for research proposals by investigators to undertake research projects in the priority areas of capacity planning, implementation projects and population health projects.

I encourage you to apply for a research grant by completing the attached application form. Please refer to the attached announcement for further details, including eligibility criteria. Applications are due by 5 pm (EDT) to the CCO Research Office (research@cancercare.on.ca). 

Please feel free to share this with any researcher in Ontario within your network who might be interested in applying for a research grant. I appreciate your assistance.

 Sincerely,

 Jason Garay BSc, BASc, MHSc
Vice President
Analytics & Informatics

Adjunct Professor, University of Toronto

CCO | Our future health built with care
620 University Ave., Toronto, ON M5G 2L7

www.cancercare.on.ca

⇒C17 Operating and Ewing Sarcoma Grant Competition. Registration due 08-Sep-17. Grants due 29-Sep-17. All areas of research welcome. Spread the word!!

A reminder that the registration for the C17 Operating and Ewing Sarcoma Grant Competitions are due on 08-Sep-17. Grants due are 29-Sep-17.

Miss the original call?  You can find the call and forms at:

The B+ Foundation has opened their grant competition for two-year grants at $150,000 USD (10-12 available). Open to Canadian researchers. Competition closes 15-Sept-2017. bepositive.org

bepositive.org/research/

The Andrew McDonough B+ Foundation is proud to announce the 2017 Research Grant Cycle is now open.

Applications can be submitted at Proposal Central from June 1 to September 15, 2017 atbepositive.org/research/.  Our Scientific Advisory Board will then review applications and award 10-12 two-year grants of $75,000/year for a total award of $150,000 each.

Would you like $1000? If you are a non-MD healthcare professional working in peds hem/onc/BMT, you are eligible to apply for $1000 off-set the cost of attending a work-related conference. Applications due Nov 1 and May 1, annually.

See the Norma Auger application form available HERE; includes additional eligibility and instruction. 

The goal of the C17 Norma Auger Education Fund is to support health professionals involved in pediatric Oncology/Hematology/BMT across Canada advance their knowledge, skills and experience and to promote presentations and knowledge translation by these health professionals.  This is an annual scholarship offered by the C17 Education Committee with funding from the Childhood Cancer Canada Foundation.

Eligibility: Non-MD Pediatric Oncology/Hematology/BMT health care professionals working in Canada.

Application deadlines:  May 1st and November 1st annually  Selection Process: Applications will be reviewed by the C17 Education Committee.  Successful applicants will be notified in writing by December 1st and June 1st.

NEW⇒C17 Operating and Ewing Sarcoma Grant Competition. Registration due 08-Sep-17. Grants due 29-Sep-17. All areas of research welcome. Spread the word!!

C17 is pleased to announce a SUPPLEMENTAL GRANT COMPETITION for both the C17 Research Network Operating Grant Competition (Round 20) and the Ewing Sarcoma Grant Competition (Round 5). This competition does not replace the regular fall competition.  It is an additional funding opportunity.

The C17 operating grant competition is focused on multicenter, multidisciplinary pediatric oncology/hematology research. The Ewing Sarcoma Competition is focused on research with a direct application into the causes, treatment, cure and quality of life for young people with Ewing Sarcoma.

Forms and documents can be found attached as linked above, and can be downloaded from www.c17.ca/council-and-administrators/research/ under Committees> Research Network.

If you have any questions, please contact the C17 Research Network Coordinator, Leah C. Young, Ph.D.  leah.young2 (at) ahs.ca

Alex’s Lemonade Stand “Reach Grant” (preclinical focus, $250,000/2yrs) and “A Award” (early career support, $800,000/4yrs) applications due May 22, 2017

‘A’ Award Program Goals

www.alexslemonade.org/sites/default/files/2017_a-award_guidelines_final.pdf

  • To encourage the best and brightest early career independent researchers to build lifelong careers and become leaders in the field of pediatric cancer research.
  • To advance research that will lead to new treatments and cures impacting children with cancer.
  • Initial Awards are for $800,000 over 4 years (no more than $200,000 in any given year).
  • Funds must be granted to non-profit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.

Reach Grants

www.alexslemonade.org/sites/default/files/2017_reach_guidelines_final.pdf

  • To support important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial; selected late translational studies.
  • Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.
  • Maximum of $125,000 in total costs may be requested per year.
  • Funds must be granted to non-profit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.

Survivorship and Palliative End-of-Life CCRA Research Frameworks released March 2017

The CCRA research frameworks were developed to guide Canada’s cancer research funders in their response to the recommendations in Target 2020, CCRA’s current strategic plan. Their intent is to identify research priorities to enable coordinated action among CCRA members, other funders, and key stakeholders with the goal of optimizing the excellence, relevancy, and impact of cancer research in Canada.

The Pan-Canadian Frameworks for Cancer Survivorship Research and Palliative and End-of-Life Care Research are now available through the CCRA website.

English

www.ccra-acrc.ca/index.php/publications-en/strategy-related-publications

Français

www.ccra-acrc.ca/index.php/fr/publications-fr/strategie-publications-connexes

CCSRI – change of deadline dates for upcoming competitions

CCSRI announced their upcoming competition deadlines, and included the note that some dates have changed. Details will be made available shortly for the following:
  • Knowledge to Action grants (abstract registration deadline April 1; funding start November 1, 2017)
  • Impact grants (letter of intent deadline April 3; funding start February 1, 2018)
  • Innovation grants with a focus only on prevention  (abstract registration deadline May 1; funding start November 1, 2017)
  • Quality of Life grants (letter of intent deadline May 15; funding start February 1, 2018)

Visit the CCSRI website for information: www.cancer.ca/research

 

Are you following CAR-T and other immunotherapy research in Canada? BioCanRx has announced $11 million investment in 16 collaborative research projects in novel therapies to cure cancer, including funding to manufacture the first made-in-Canada CAR-T cells.

OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET – BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer, including research aimed at developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada.

BioCanRx is investing in research projects advancing several innovative engineered T cell designs, which will further benefit from this infrastructure and capacity investment, and accelerate delivery of these novel concepts into clinical testing in Canada. This Canadian capacity development will pave the way to enable Canadian patients to access this new technology, and will give Canadian researchers the necessary resources to deliver on their innovations in CAR-T and other engineered T cell platforms. This CAR-T manufacturing initiative is unique in that the Canadian academic community recognized a gap and stepped up to drive Canadian solutions to meet grassroots efforts taking place in the U.S., China and Europe.

To help ensure CAR-T cell therapy is brought to patients safely and effectively, BioCanRx is funding a companion Clinical, Social, and Economic Impact project. It will review the existing base of knowledge and involve patient consultation to design a rigorous CAR-T clinical trial protocol ready to implement once the products are ready for a phase 1 clinical trial.